Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη κολιμυκίνης σε βρέφη και παιδιά με λοιμώξεις από πολυανθεκτικά Gram-αρνητικά βακτήρια

Abstract

dc:description

The wide spread of multidrug resistant Gram-negative bacteria is worrying, since the infections caused by these pathogens are related to increased morbidity and mortality, while their ability to form biofilms makes their treatment even more difficult. Colistin is a last-resort therapeutic option with high potency against multidrug resistant Gram-negative bacteria. Limited pharmacokinetic data suggest that currently recommended pediatric dosages of colistimethate sodium (CMS) by the Food and Drug Administration and European Medicines Agency may lead to suboptimal exposure, resulting in plasma colistin concentrations that are frequently < 2 μg/mL. The aim of this study was to investigate the pharmacodynamic and immunomodulatory effects of colistin against biofilms of multidrug resistant Klebsiella pneumoniae in vitro, and the pharmacokinetics of this drug in pediatric patients, at dosages higher than currently recommended. We investigated the bactericidal activities of colistin, rifampin, meropenem, gentamicin, and tigecycline alone, and that of colistin in combination with rifampin, meropenem, gentamicin, or tigecycline against carbapenem-resistant K. pneumoniae mature biofilms. Twenty carbapenem-resistant K. pneumoniae blood isolates were derived from an equal number of bloodstream infections in adult patients. Biofilm formation was assessed by crystal violet method. Biofilm damage was measured as the percent reduction of metabolic activity by XTT assay. The MIC50 for biofilms was determined as the minimum concentration that caused ≥ 50% bacterial damage compared to that for untreated controls. Antibacterial drug interactions were analyzed using the Bliss independence model. Furthemore, the interactions between colistin and innate immune cells against carbapenem-resistant K. pneumoniae biofilms were investigated, by studying the effect of biofilm sub-MICs of colistin on (i) damage induced by human polymorphonuclear neutrophils (PMNs) on carbapenem-resistant K. pneumoniae biofilms and (ii) the immunomodulatory potential of human mononuclear cells (MNCs) exposed to carbapenem-resistant K. pneumoniae biofilms. The impact of colistin on PMN-induced biofilm damage was assessed by XTT reduction assay. Signal transduction and gene expression profiles in response to colistin sub-MICs of MNCs exposed to carbapenem-resistant K. pneumoniae biofilms were studied by RT-PCR and multiplex ELISA. Four of the 20 carbapenem-resistant K. pneumoniae isolates that were evaluated were biofilm producers. Biofilm MIC50s of colistin, rifampin, meropenem, gentamicin, and tigecycline for these isolates were 64, 8, > 256, 128, and 8 μg/mL, respectively. Synergistic interactions were observed at 32- 64 μg/mL of colistin combined with 0.25- 4 μg/mL of rifampin, at 32 μg/mL of colistin combined with 0.007- 0.25 μg/mL of meropenem, and at 16- 32 μg/mL of colistin combined with 16- 64 μg/mL of tigecycline. The synergy was highest for colistin plus rifampin, with a mean ΔE ± standard error (SE) of 49.87% ± 9.22%, compared to 29.52% ± 4.97% for colistin plus meropenem (p < 0.001) and 32.44% ± 6.49% for colistin plus tigecyline (p < 0.001). Indifferent interactions were demonstrated for colistin plus gentamicin. None of the combinations exhibited antagonism. Pre-exposure of carbapenem-resistant K. pneumoniae to 0.06 μg/mL of colistin led to subsequent increased PMN-mediated biofilm damage against carbapenem-resistant K. pneumoniae biofilms in the presence of colistin biofilm sub-MICs, with an additive effect at 2, 4, 8 and 16 μg/mL. However, the overall biofilm damage did not exceed 52%. MNCs responded to carbapenem-resistant K. pneumoniae biofilms through TLR2 by 2.5-fold upregulation and NLRP3 inflammasome activation. Carbapenem-resistant K. pneumoniae biofilms stimulated increased production of inflammatory cytokines IL-1β, TNF-α, IL-8 and IL-6. In the combination treatment, 0.5 μg/mL of colistin reduced IL-1β, TNF-α and IL-8 levels, whereas at 2 μg/mL and 8 μg/mL it increased the anti-inflammatory cytokine IL-10 (p < 0.05). To evaluate pharmacokinetics (PK) of colistin in children, we conducted a population PK study in 17 critically ill patients 3 months to 13.75 years (median, 3.3 years) old who received CMS for infections caused by carbapenem-resistant Gram-negative bacteria. CMS was dosed at 200,000 IU/kg/day (6.6 mg colistin base activity [CBA]/kg/day; 6 patients), 300,000 IU/kg/day (9.9 mg CBA/kg/day; 10 patients), and 350,000 IU/kg/day (11.6 mg CBA/kg/day; 1 patient). Plasma colistin concentrations were determined using ultra performance liquid chromatography (UPLC) combined with electrospray ionization-tandem mass spectrometry (ESI-MS/MS). Population PK modeling of colistin in plasma was conducted using the first-order conditional estimation algorithm with interaction (FOCE+I) in NONMEM. Various parameters were recorded that could possibly be implicated in colistin PK, as well as infection- or treatment-related data. Patients were clinically and laboratory monitored for adverse events. Colistin PK was described by a one-compartment disposition model, including creatinine clearance, body weight, and the presence or absence of systemic inflammatory response syndrome (SIRS) as covariates (p < 0.05 for each). The average colistin plasma steady-state concentration (Css,avg) ranged from 1.11 to 8.47 μg/mL (median, 2.92 μg/mL). Ten patients had Css,avg of ≥ 2 μg/mL. The presence of SIRS was associated with decreased apparent clearance of colistin (47.8% of that without SIRS). The relationship between the number of milligrams of CBA per day needed to achieve each 1 μg/mL of plasma colistin Css,avg and creatinine clearance (in mL/min) was described by linear regression with different slopes for patients with and without SIRS. Nephrotoxicity, probably unrelated to colistin, was observed in one patient. In conclusion, colistin, in high doses, exhibited significant activity against carbapenem-resistant K. pneumoniae biofilms, and a remarkable synergistic effect with rifampicin, meropenem, and tigecycline. Biofilm sub-MICs of the drug improved PMNs’ killing capacity, and inhibited the excessive production of inflammatory cytokines by MNCs exposed to K. pneumoniae biofilms, emphasizing its beneficial effect on human immune cells. Regarding its use in pediatric patients, administration of CMS at the above, higher than recommended, doses improved exposure and was well tolerated. Population PK analysis identified creatinine clearance and the presence or absence of SIRS as important covariates for the apparent clearance of colistin. The development of a generalizable dosing algorithm for pediatric patients however was not feasible, as significant interpatient variability was observed when patients from previous studies were included in the analysis.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Geladari, Anastasia
  • Γελαδάρη, Αναστασία

Subjects

dc:subject × 30

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/50652

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Geladari, Anastasia; Γελαδάρη, Αναστασία. Μελέτη κολιμυκίνης σε βρέφη και παιδιά με λοιμώξεις από πολυανθεκτικά Gram-αρνητικά βακτήρια. Aristotle University Of Thessaloniki (AUTH), 2021. http://hdl.handle.net/10442/hedi/50652